ClinicalTrials.gg
CompletedNCT07282054Updated Dec 15, 2025

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

A Phase 3 interventional study of THDB0206 and Insulin Lispro in Type 1 Diabetes, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Apr 2022, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Diabetes Mellitus, Type 1 with a site in China — 42 open to participants now, 45 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · China.

Enrollment
4th of 83
550 · median 50
Started
2022
with 7 others
Phase 3
12 of 103
2 open now
Registered
92nd of 103
by date

Among the 103 studies in Diabetes Mellitus, Type 1 with a site in China, this one is the 4th largest by enrollment of the 83 interventional ones that give a count, is one of 8 that started in 2022, is one of 12 in phase 3, and was the 92nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

42 of the 103 studies in Diabetes Mellitus, Type 1 with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Diabetes Mellitus, Type 1 with a site in China, or all of them as a file.
02

Study summary

This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin glargine injection U-100 in Chinese participants with T1DM.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants, 18 to 75 years of age at (inclusive).
  2. between 18.0 and 30.0 kg/m² (inclusive).
  3. T1DM diagnosed ≥6 months per WHO diabetes classification (2019).
  4. On insulin therapy ≥6 months prior to screening.
  5. Stable insulin regimen ≥3 months prior to screening (no change in insulin class), with or without metformin or alpha-glucosidase inhibitors; willing to follow multiple daily injections:

    1. Intermediate/long-acting insulin once or twice daily (e.g., NPH, glargine, detemir, degludec); plus prandial insulin 1\~3 times daily (or as per usual diet) (e.g., regular human insulin, lispro, aspart, glulisine).
    2. Premixed insulin ≥2 times per day.
  6. Screening between 7.0% and 11.0% (inclusive), measured by the central laboratory.

Exclusion criteria

Exclusion Criteria:

  1. Diabetes other than T1DM.
  2. History of pancreatectomy.
  3. Prior pancreatic and/or islet cell transplantation.
  4. ≥1 episode of Level 3 hypoglycemia within 6 months before screening (requires external assistance).
  5. Hepatic or renal impairment at screening (per local laboratory reference ranges):

    1. or ALT ≥3× ; and/or
    2. TBL ≥2× ULN (except Gilbert syndrome); and/or
    3. Estimated \<45 mL/min (Cockcroft-Gault).
  6. Known /allergy to study insulin products or , or to any component of the standardized test meal.
  7. Blood transfusion or major blood loss within 3 months before screening; hemoglobinopathies, moderate-severe anemia, or other conditions that may interfere with measurement.
  8. Use of oral antihyperglycemics within 3 months before screening (except metformin and alpha-glucosidase inhibitors), or use of non-insulin injectables (e.g., GLP-1 receptor agonists).
  9. Systemic therapy for ≥14 consecutive days within 3 months prior to screening (including IV, IM, SC, or oral routes; excluding topical, intraocular, intranasal, intra-articular, and inhaled use), or systemic corticosteroid therapy within 8 weeks prior to screening (except physiologic replacement for adrenal insufficiency), or anticipated need for prolonged systemic corticosteroid therapy during the study.
  10. Use within 3 months before screening, or current use, of traditional medicines (herbal or proprietary Chinese medicines) with known glucose-lowering effects.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (actual)

Study arms

  • Experimental
    THDB0206 Injection

    Drug: THDB0206 · Drug: Insulin Glargine

  • Active comparator
    Insulin Lispro Injection

    Drug: Insulin Lispro · Drug: Insulin Glargine

Interventions

  • Subcutaneous THDB0206 three times daily, with individualized dose adjustment.

  • Subcutaneous insulin lispro three times daily, with individualized dose adjustment.

  • Subcutaneous insulin glargine once daily, with individualized dose adjustment.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in HbA1c at Week 26

    Time frame: Week 26

Secondary outcomes

  1. Change from Baseline in 1-hour Postprandial Glucose (PPG) Excursion at Week 26

    Time frame: Week 26

  2. Change from Baseline in 2-hour Postprandial Glucose (PPG) Excursion at Week 26

    Time frame: Week 26

07

Study locations

1 site
  • Nanjing Drum Tower hospital
    Nanjing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jan 2025, 33 months.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 33 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 15, 2025
StartActual
Apr 13, 2022
Primary completionActual
Jan 23, 2025
CompletionActual
Jan 24, 2025
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07282054
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Apr 13, 2022
Primary completion
Jan 23, 2025
Completion
Jan 24, 2025
Last update
Dec 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THDB0206

Start the discussion